Frequently Asked Questions about bioAffinity Technologies, Inc. (BIAF)

Name: bioAffinity Technologies, Inc. (BIAF) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does bioAffinity Technologies, Inc. (BIAF) do?

Accepted Answer

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular ...

Question 2

Is bioAffinity Technologies, Inc. (BIAF) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of BIAF reveals an Altman Z-Score of -9.15 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.01B most recent), help investors decide if BIAF fits their risk profile.

Question 3

What is the current P/E ratio for BIAF?

Accepted Answer

As of the latest trading session, bioAffinity Technologies, Inc. (BIAF) has a trailing P/E ratio of -0.47.

Question 4

Who is the CEO of bioAffinity Technologies, Inc.?

Accepted Answer

The current Chief Executive Officer of bioAffinity Technologies, Inc. is Maria Zannes.

Question 5

What was BIAF's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, bioAffinity Technologies, Inc. reported annual revenues of $0.01B (2025), $0.01B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does BIAF pay a dividend?

Accepted Answer

bioAffinity Technologies, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does BIAF have?

Accepted Answer

In its latest reporting period, bioAffinity Technologies, Inc. generated $-0.01B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of bioAffinity Technologies, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for bioAffinity Technologies, Inc. (BIAF) is currently 0.97.

Question 9

What is the Price-to-Sales (P/S) ratio of BIAF?

Accepted Answer

Based on trailing twelve-month data, bioAffinity Technologies, Inc. (BIAF) trades at a Price-to-Sales (P/S) ratio of 2.99.

Question 10

What is bioAffinity Technologies, Inc.'s Return on Equity (ROE)?

Accepted Answer

bioAffinity Technologies, Inc. (BIAF) has a Return on Equity (ROE) of -385.19%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	6.2M	1.4M	-10.6M	-14.9M	-8.66
2024-12	9.4M	3.4M	-9M	-9M	-22.50
2023-12	2.5M	791.6K	-8M	-7.9M	-27.30
2022-12	4.8K	4.3K	-4M	-8.2M	-54.30
2021-12	0	-4.8K	-2.2M	-6.3M	-70.86

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	6.2M	1.4M	-10.6M	-14.9M	-8.66
2024-12	9.4M	3.4M	-9M	-9M	-22.50
2023-12	2.5M	791.6K	-8M	-7.9M	-27.30
2022-12	4.8K	4.3K	-4M	-8.2M	-54.30
2021-12	0	-4.8K	-2.2M	-6.3M	-70.86